Michael Giordano
Director/Board Member at RAPT THERAPEUTICS, INC.
Net worth: 36 117 $ as of 30/04/2024
Michael Giordano active positions
| Companies | Position | Start | End |
|---|---|---|---|
| RAPT THERAPEUTICS, INC. | Director/Board Member | 01/01/2018 | - |
| Independent Dir/Board Member | 01/01/2018 | - | |
| ACHILLES THERAPEUTICS PLC | Director/Board Member | 01/09/2018 | - |
| Independent Dir/Board Member | 01/09/2018 | - | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 19/09/2018 | - |
Oncovalent Therapeutics, Inc.
 Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Director/Board Member | - | - |
Career history of Michael Giordano
Former positions of Michael Giordano
| Companies | Position | Start | End |
|---|---|---|---|
| EPIZYME, INC. | Director/Board Member | 01/08/2018 | 12/08/2022 |
| Chief Tech/Sci/R&D Officer | 01/12/2017 | 01/08/2018 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/02/2012 | 01/02/2017 |
| Weill Cornell Medicine | Corporate Officer/Principal | - | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - | - |
Training of Michael Giordano
| The Johns Hopkins University | Undergraduate Degree |
| Weill Cornell Medicine | Doctorate Degree |
Statistics
International
| United States | 6 |
| 2 | |
| United Kingdom | 2 |
Operational
| Director/Board Member | 5 |
| Corporate Officer/Principal | 3 |
| Independent Dir/Board Member | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
 | Health Technology |
| Private companies | 5 |
|---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
| Rapt Therapeutics, Inc. | |
| Achilles Therapeutics Plc | |
Oncovalent Therapeutics, Inc.
Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Michael Giordano
- Experience
